Femasys Inc (FEMY) Stock Analysis
Verdict: AVOID
A $30M private placement extends runway for FemBloc trials, but an annual burn of $18.7M on $2.3M revenue creates heavy dilution risk.
Investment score: 33/100
Analysis as of
Is Femasys Inc stock worth reviewing? AI model thesis
The model assigns an AVOID recommendation on FEMY due to persistent high operating burn ($18.7M/yr), dilution risk from warrant overhang, and severe technical downward momentum despite recent $30M financing.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Femasys Inc opportunities and risks
What speaks for FEMY
- FemBloc FDA Modular PMA Pathway Authorization
What speaks against FEMY
- High Operational Cash Burn and Ongoing Capital Need
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| FEMY | n/a | 2.7x | n/a | 52.2% | -534.3% | -293.4% |
| RDGL | n/a | 233.7x | n/a | -344.1% | -3633.3% | -10.8% |
| PMI | n/a | 3.2x | n/a | 25.0% | -444.3% | -80.6% |
| PAVM | n/a | 153.3x | n/a | -254.5% | -10794.6% | -15288.7% |
| GTHP | n/a | 29.7x | n/a | 64.0% | -573.1% | -7.8% |
| Peer median | n/a | 91.5x | n/a | -114.7% | -2103.2% | -45.7% |
Frequently asked questions about Femasys Inc (FEMY)
Is FEMY stock a good investment?
The cached TradeMates AI model rates Femasys Inc as AVOID with an investment score of 33/100. The model assigns an AVOID recommendation on FEMY due to persistent high operating burn ($18.7M/yr), dilution risk from warrant overhang, and severe technical downward momentum despite recent $30M financing. This is algorithmic model output, not personal investment advice.
Is FEMY stock a buy?
The TradeMates model verdict for FEMY is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.